Archives of cardiovascular diseases, 2017, 110 (2), pp.69 - 71. ⟨10.1016/j.acvd.2016.12.004⟩
Anthracyclines are anticancer agents with a broad spectrum of activity in oncological practice. However, the use of anthracyclines is limited by the cardiotoxicity they may induce [1]. Following the administration of anthracyclines in the setting of adjuvant therapy for breast cancer, trastuzumab (Herceptin), a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER 2) protein, is effective in patients that overexpress this receptor [1]. The addition of trastuzumab therapy to sequential anthracycline and taxane adjuvant treatment reduced the risk of breast cancer recurrence by nearly one-half, and the risk of death by one-third [2]. However, while preclinical studies did not reveal cardiotoxicity, later clinical studies showed that treatment with trastuzumab led to an unexpected incidence of cardiac side-effects [3]. The most frequent effect was reduced systolic ventricular function, asymptomatic or associated with heart failure.
Charles Guenancia, Sylvain Ladoire, François Ghiringelli, Luc Rochette, Catherine Vergely, et al.. Implications of excess weight in the cardiotoxicity of anthracyclines and trastuzumab in breast cancer. Archives of cardiovascular diseases, 2017, 110 (2), pp.69 - 71. ⟨10.1016/j.acvd.2016.12.004⟩ (lien externe). ⟨hal-01528637⟩ (lien externe)
Citations
APA
Guenancia, C., Ladoire, S., Ghiringelli, F., Rochette, L., Vergely, C., & Cottin, Y. (2017). Implications of excess weight in the cardiotoxicity of anthracyclines and trastuzumab in breast cancer. In Archives of cardiovascular diseases. https://doi.org/10.1016/j.acvd.2016.12.004
MLA
Guenancia, Charles, et al. “Implications of Excess Weight in the Cardiotoxicity of Anthracyclines and Trastuzumab in Breast Cancer.” Archives of Cardiovascular Diseases, Jan. 2017, https://doi.org/10.1016/j.acvd.2016.12.004.
Chicago
Guenancia, Charles, Sylvain Ladoire, François Ghiringelli, Luc Rochette, Catherine Vergely, and Yves Cottin. 2017. “Implications of Excess Weight in the Cardiotoxicity of Anthracyclines and Trastuzumab in Breast Cancer.” Archives of Cardiovascular Diseases. https://doi.org/10.1016/j.acvd.2016.12.004.
Harvard
Guenancia, C. et al. (2017) “Implications of excess weight in the cardiotoxicity of anthracyclines and trastuzumab in breast cancer,” Archives of cardiovascular diseases. Available at: https://doi.org/10.1016/j.acvd.2016.12.004.
ISO 690
GUENANCIA, Charles, LADOIRE, Sylvain, GHIRINGELLI, François, ROCHETTE, Luc, VERGELY, Catherine and COTTIN, Yves, 2017. Implications of excess weight in the cardiotoxicity of anthracyclines and trastuzumab in breast cancer [en ligne]. January 2017. Disponible à l'adresse : https://doi.org/10.1016/j.acvd.2016.12.004